Penumbra(US:PEN) Financial Modeling Prep·2026-02-27 00:10Core Insights - Penumbra, Inc. is a leading company in the medical instruments sector, particularly recognized for its thrombectomy products, and has demonstrated strong financial performance in its recent earnings report [1] Financial Performance - The company reported earnings of $1.18 per share, exceeding the Zacks Consensus Estimate of $1.12, resulting in a 5.36% earnings surprise and a significant increase from $0.97 per share reported a year ago [2][6] - Revenues for the quarter ending December 2025 reached $385.39 million, surpassing the Zacks Consensus Estimate by 6.74% and reflecting a 22.1% increase compared to $315.52 million in the same period last year [3][6] Revenue Breakdown - The United States contributed 77.6% of Penumbra's total revenue, with international markets accounting for 22.4%. U.S. revenue increased by 20.6%, while international revenue grew by 27.7% [4] - Sales of global thrombectomy products amounted to $254.7 million, primarily driven by strong sales in the U.S. market [4] Stock Performance - The current trading price of PEN is $341.11, showing a 0.72% increase, with a market capitalization of approximately $13.38 billion. The stock has fluctuated between $338.82 and $341.12 today [5] - Over the past year, PEN has reached a high of $362.41 and a low of $221.26, indicating a dynamic market presence [5] Analyst Outlook - UBS has set a price target of $374 for PEN, suggesting a potential increase of about 9.92% from its current trading price of $340.24, reflecting strong investor confidence [1][6]